Eyebot takes a series of $ 20 million to extend access to eye care

EyeA starting of a 90 -second vision trial booth delivering glass recipes that verifies a doctor has secured $ 20 million in funding in Series A.

Boston -based start -up, founded in 2021, rationalize how people have access to vision care, eliminating traditional obstacles, such as delays, limited accessibility, complex insurance requirements and costs.

Its kiosks, already in shopping malls, universities, retail stores, pharmacies, grocery chains, schools and airports, provide a free 90 -second vision test. According to the company, each test creates a recipe that is then revised and approved by licensed eye doctors, ensuring fast, convenient and reliable recipes.

The new funding, which brings Eyebot’s total funding to more than $ 30 million, comes about a year after the start of its seeds in June 2024. Since then, the start has carried out more than 45,000 free vision tests and is on the right track to surrender.

“From our seeds, the shift was dramatic. We have passed through the pilot cooperation with some of the largest companies in the US, starting kiosks across the country and providing tens of thousands of vision tests,” said Matthias Hofmann, co -founder and CEO of Eyebot. “Revenue is escalating and our team has doubled in size. Most importantly, we have proven that the model works: people use Eyebot, doctors are validating results and retailers are excited about the circulation it drives.”

What Eyebot puts, Hofmann said, is the combination of convenience and medical assurance. Each test is examined by a doctor and all prescriptions are issued under clinical supervision. If the test results indicate something unusual, patients report on personal, integrated exams. This balance of speed plus clinical supervision gains confidence, he says.

“In our locations, we have seen amazing recruitment from parents with children,” Hofmann said. “They will stop between the stores. They will try Eyebot – sometimes even if you hold their children’s hands – and leave with a recipe in a few minutes.”

The persuasion of traditional eye care providers to embrace a technical-first approach has proven to be difficult. The first skepticism ran deeply: doctors were worried about precision, while patients questioned whether a procedure could be reliable so quickly, according to Hofmann. He says that the hesitation has been relaxed when providers learned that experienced doctors are reviewing every result, many with over a decade of experience.

Eyebot is in the early stages of commercialization. Its vision test is offered free of charge to consumers and, if required for a prescription, one of the company doctors verifies it for a fee. In addition, the company leases its kiosks to optical retailers, glasses and independent practices.

In series A, the company plans to scale the growth of Kiosk and extend its team to products, clinical businesses and commercial development, the CEO said.

The last round was head of General Catalyst and included the participation of investor returns Alleycorp, Baukunst, Village Global, Humba Venture, Ravelin and Ubiquity Ventures.